Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Contrast-enhanced magnetic resonance imaging (MRI) remains the most comprehensive modality to assess juvenile idiopathic arthritis (JIA)-related inflammation and osteochondral damage in the temporomandibular joints (TMJ). This study tested the reliability of a new JIA MRI scoring system for TMJ (JAMRIS-TMJ) and the impact of variations in calibration and reader specialty. Thirty-one MRI exams of bilateral TMJs were scored independently using the JAMRIS-TMJ by 20 readers consisting of radiologists and non-radiologist clinicians in three reading groups, with or without a calibrating atlas and/or tutorial. The inter-reader reliability in the multidisciplinary cohort assessed by the generalizability coefficient was 0.61-0.67 for the inflammatory and 0.66-0.74 for the damage domain. The atlas and tutorial did not improve agreement within radiologists, but improved the agreement between radiologist and non-radiologist groups. Agreements between different calibration levels were 0.02 to 0.08 lower by the generalizability coefficient compared to agreement within calibration levels; agreement between specialty groups was 0.04 to 0.10 lower than within specialty groups. Averaging two radiologists raised the reliability above 0.8 for both domains. Therefore, the reliability of JAMRIS-TMJ was moderate-to-good depending on the presence of specialty and calibration differences. The atlas and tutorial are necessary to improve reliability when the reader cohort consists of multiple specialties.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467699PMC
http://dx.doi.org/10.3390/jcm10184047DOI Listing

Publication Analysis

Top Keywords

juvenile idiopathic
8
idiopathic arthritis
8
magnetic resonance
8
scoring system
8
temporomandibular joints
8
generalizability coefficient
8
atlas tutorial
8
tutorial improve
8
calibration levels
8
specialty groups
8

Similar Publications

Background: Arthritis affects millions of people worldwide; however, its mismanagement remains a growing global challenge, resulting in reduced quality of life (QoL) and disability. Digital health (DH), including smartphones, could be the key to solving this problem. Specific evidence-based reviews on the use of DH in this context are lacking.

View Article and Find Full Text PDF

Walking By Faith.

J Christ Nurs

September 2025

Christy Jeffcoat, DNP, RN, EBP-C, is an assistant professor at University of South Carolina College of Nursing. Her areas of interest include women's health, maternal mental health, juvenile idiopathic arthritis, lateral violence in nursing, and various aspects of evidence-based practice.

View Article and Find Full Text PDF

Background: Baricitinib has previously been shown to improve clinical response in patients with juvenile idiopathic arthritis (JIA) in the JUVE-BASIS trial. In this post-hoc analysis we aimed to identify whether pharmacodynamic changes in serum biomarkers in response to baricitinib treatment could help reaffirm the clinical utility of baricitinib in patients with JIA.

Methods: JUVE-BASIS was a randomised, double-blind, placebo-controlled, withdrawal, efficacy, safety, phase 3 trial, done in 75 centres in 20 countries.

View Article and Find Full Text PDF

Biomarkers for juvenile idiopathic arthritis treatment response-have we identified them?

Lancet Rheumatol

September 2025

Section of Rheumatology, Department of Pediatrics, Alberta Children's Hospital, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. Electronic address:

View Article and Find Full Text PDF

Objective: To describe the efficacy and safety of tofacitinib for pediatric Still's disease, also referred to as systemic-onset juvenile idiopathic arthritis (sJIA). Traditional non-biological drugs and drugs targeting the interleukin-1 and interleukin-6 pathways benefit some patients, but others show inadequate responses.

Methods: We retrospectively analyzed ten patients with pediatric Still's disease who were treated with tofacitinib and had at least one follow-up visit.

View Article and Find Full Text PDF